Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7REW

Crystal Structure of IL-13 in complex with MMAb3 Fab

7REW の概要
エントリーDOI10.2210/pdb7rew/pdb
分子名称anti-cyno interleukin 13 Fab heavy chain, anti-cyno interleukin 13 Fab light chain, IL13, ... (4 entities in total)
機能のキーワードalpha-helical bundle, protein-fab complex, cytokine
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数6
化学式量合計118296.46
構造登録者
Sudom, A.,Min, X. (登録日: 2021-07-13, 公開日: 2022-05-25, 最終更新日: 2024-10-16)
主引用文献Kielczewska, A.,D'Angelo, I.,Amador, M.S.,Wang, T.,Sudom, A.,Min, X.,Rathanaswami, P.,Pigott, C.,Foltz, I.N.
Development of a potent high-affinity human therapeutic antibody via novel application of recombination signal sequence-based affinity maturation.
J.Biol.Chem., 298:101533-101533, 2022
Cited by
PubMed Abstract: Therapeutic antibody development requires discovery of an antibody molecule with desired specificities and drug-like properties. For toxicological studies, a therapeutic antibody must bind the ortholog antigen with a similar affinity to the human target to enable relevant dosing regimens, and antibodies falling short of this affinity design goal may not progress as therapeutic leads. Herein, we report the novel use of mammalian recombination signal sequence (RSS)-directed recombination for complementarity-determining region-targeted protein engineering combined with mammalian display to close the species affinity gap of human interleukin (IL)-13 antibody 731. This fully human antibody has not progressed as a therapeutic in part because of a 400-fold species affinity gap. Using this nonhypothesis-driven affinity maturation method, we generated multiple antibody variants with improved IL-13 affinity, including the highest affinity antibody reported to date (34 fM). Resolution of a cocrystal structure of the optimized antibody with the cynomolgus monkey (or nonhuman primate) IL-13 protein revealed that the RSS-derived mutations introduced multiple successive amino-acid substitutions resulting in a de novo formation of a π-π stacking-based protein-protein interaction between the affinity-matured antibody heavy chain and helix C on IL-13, as well as an introduction of an interface-distant residue, which enhanced the light chain-binding affinity to target. These mutations synergized binding of heavy and light chains to the target protein, resulting in a remarkably tight interaction, and providing a proof of concept for a new method of protein engineering, based on synergizing a mammalian display platform with novel RSS-mediated library generation.
PubMed: 34973336
DOI: 10.1016/j.jbc.2021.101533
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.1 Å)
構造検証レポート
Validation report summary of 7rew
検証レポート(詳細版)ダウンロードをダウンロード

248942

件を2026-02-11に公開中

PDB statisticsPDBj update infoContact PDBjnumon